Markets:

Overview

News

Currencies

International

Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

535.22 -11.84 (-2.16%)

Streaming Delayed Price Updated: 11:35 AM EDT, Jul 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

2 Safe-and-Steady Stocks with Impressive Fundamentals and 1 We Avoid

November 02, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

United Therapeutics Corp (NASDAQ:UTHR) Offers Affordable Growth with Strong Profitability ↗

October 31, 2025

United Therapeutics offers strong growth, high profitability, and a robust balance sheet, yet trades at a significant discount to the biotech industry. A top pick for affordable growth.

Via Chartmill

United Therapeutics (UTHR) Earnings Transcript ↗

October 30, 2025

United Therapeutics (UTHR) Earnings Transcript

Via The Motley Fool

Topics Earnings Intellectual Property

Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports ↗

October 30, 2025

Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls.

Via Investor's Business Daily

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

UTHR Q3 Deep Dive: Clinical Pipeline Advances and High-Dose Product Launches Drive Outlook

October 30, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 6.8% year on year to $799.5 million. Its GAAP profit of $7.16 per...

Via StockStory

Why Is United Therapeutics (UTHR) Stock Soaring Today

October 29, 2025

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 11.7% in the afternoon session after the company reported record third-quarter financial results and announced positive outcomes...

Via StockStory

Caterpillar Posts Upbeat Q3 Results, Joins United Therapeutics, Centene, Fortive And Other Big Stocks Moving Higher On Wednesday ↗

October 29, 2025

Via Benzinga

S&P 500 Tops 6,900 Ahead Fed Rate Move, Gold Reclaims $4,000: What's Moving Markets Wednesday? ↗

October 29, 2025

A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the past two sessions — propelled the S&P 500 above the 6,900 mark and lifted the Nasdaq 100 to 26,100...

Via Benzinga

Topics Economy Stocks

United Therapeutics Dips As Bread-And-Butter Drug Comes Up Short ↗

October 29, 2025

Shares of United Therapeutics slipped slightly Wednesday on light sales of its bread-and-butter drug, Tyvaso.

Via Investor's Business Daily

United Therapeutics Corp (NASDAQ:UTHR) Reports Q3 2025 Earnings: Revenue Misses, EPS Beats Estimates ↗

October 29, 2025

United Therapeutics posts record Q3 2025 revenue of $799.5M, driven by strong Tyvaso growth. The company beat EPS estimates but slightly missed on revenue.

Via Chartmill

United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q3 Earnings

October 29, 2025

Via StockStory

United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results

October 29, 2025

From United Therapeutics Corporation

Via Business Wire

A Peek at United Therapeutics's Future Earnings ↗

October 28, 2025

Via Benzinga

United Therapeutics (UTHR) Reports Q3: Everything You Need To Know Ahead Of Earnings

October 27, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings this Wednesday before the bell. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

If You Invested $100 In United Therapeutics Stock 15 Years Ago, You Would Have This Much Today ↗

October 21, 2025

Via Benzinga

United Therapeutics Forges Ahead with Share Repurchases, Not Dividends, Following July 2025 Volume Surge

October 17, 2025

In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market...

Via MarketMinute

Topics Retirement

United Therapeutics Corp (NASDAQ:UTHR) Meets Key Peter Lynch Investment Criteria ↗

October 16, 2025

United Therapeutics (UTHR) aligns with Peter Lynch's investment strategy, showing strong earnings growth, a fair PEG ratio, and a debt-free balance sheet for long-term value.

Via Chartmill

United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025

October 15, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Prime Value Investment Candidate ↗

October 14, 2025

United Therapeutics (UTHR) is a strong value stock with a low P/E ratio, zero debt, high profitability, and solid growth, making it an undervalued biotech pick.

Via Chartmill

1 Value Stock for Long-Term Investors and 2 Facing Headwinds

October 14, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

Via StockStory

United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting

October 13, 2025

From United Therapeutics Corporation

Via Business Wire

2 Growth Stocks with All-Star Potential and 1 Facing Headwinds

October 08, 2025

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Via StockStory

This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

September 26, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...

Via Benzinga

United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis

September 19, 2025

From United Therapeutics Corporation

Via Business Wire

1 Momentum Stock to Target This Week and 2 We Brush Off

September 19, 2025

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant...

Via StockStory

3 Big Reasons to Love United Therapeutics (UTHR)

September 19, 2025

United Therapeutics currently trades at $412.41 and has been a dream stock for shareholders. It’s returned 308% since September 2020, tripling the S&P 500’s 103% gain. The company has also beaten the...

Via StockStory

Topics Stocks

United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Top Peter Lynch-Style GARP Investment ↗

September 17, 2025

United Therapeutics (UTHR) aligns with Peter Lynch's GARP strategy, featuring strong EPS growth, a PEG below 1, zero debt, and robust financial health.

Via Chartmill

United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum

September 16, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress

September 12, 2025

From United Therapeutics Corporation

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.